Study Links GLP-1 Drugs to Lower Cancer Risk

A JAMA Network Open study compares obesity-related cancer rates among Type 2 diabetes patients using GLP-1 medications and other diabetes treatments.

Updated on Nov. 8, 2026 in Diabetes

Isometric editorial illustration of an unlabeled white injectable pen with a pale blue cap beside a glass vial on a clean cream surface. — Researchers reported in JAMA Network Open that Type 2 diabetes patients starting GLP-1 drugs had lower obesity-related cancer rates than those starting insulin or sulfonylureas. AI Illustration. Upload story photo >

Live Poll

Would you consider a weight-loss drug partly for lowering future cancer risk?

Researchers published a study in JAMA Network Open finding that people with Type 2 diabetes who started GLP-1 medications had lower rates of obesity-related cancers than those who started insulin and sulfonylureas. The lower rates were particularly observed among adults with less severe diabetes.

Why it matters

Obesity is a known risk factor for at least 13 types of cancer, according to the American Cancer Society, so the findings add to questions about how widely used weight-loss and diabetes drugs may affect long-term health. The study does not definitively prove that GLP-1 medications directly prevent cancer.

The JAMA Network Open cohort compared GLP-1 starters with insulin and sulfonylurea starters over three- and five-year follow-up periods, with lower obesity-related cancer rates seen in the GLP-1 group. The findings were not consistent across all other diabetes drugs, and the study cannot confirm a direct preventive effect.

The players

JAMA Network Open

JAMA Network Open is an open-access, peer-reviewed medical journal published by the American Medical Association.

American Cancer Society

The American Cancer Society is a nationwide voluntary health organization focused on cancer research, prevention, and patient support.

The details

Researchers compared people with Type 2 diabetes who started GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Trulicity, with people who started other diabetes treatments. Patients were followed over three-year and five-year periods to track cancer outcomes.

Patients were followed over three-year and five-year periods in the study.
The article about the study was published on November 7, 2026.

Health Landscape

The American Cancer Society has long identified obesity as a risk factor for at least 13 types of cancer. This study extends that established link to ask whether GLP-1 medications used for diabetes and weight loss may alter cancer risk across patient groups.

Patients taking GLP-1 medications for Type 2 diabetes should discuss the study's findings with their doctors, since it shows an association rather than proof of prevention. Anyone considering these drugs for diabetes or weight management should weigh the known benefits and risks with a healthcare provider.

The takeaway

The findings suggest a possible association between GLP-1 use and lower obesity-related cancer risk, but they do not prove prevention. Readers managing diabetes should keep following their doctor's guidance rather than changing treatment based on this study alone.